Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phellamurin SCHEMBL27013577 | 0.94 | PTPN1 (0.47) | PTPN1SLCO2B1SLC28A3ABCG2SLC5A1 | |
| Phellamurin SCHEMBL30291874 | 0.94 | PTPN1 (0.47) | PTPN1SLCO2B1SLC28A3ABCG2SLC5A1 | |
| SCHEMBL19463534 | 0.81 | PTPN1 (0.62) | PTPN1SLCO2B1ABCG2ACHEKDM1A | |
| SCHEMBL19463533 | 0.81 | PTPN1 (0.62) | PTPN1SLCO2B1ABCG2ACHEKDM1A | |
| SCHEMBL19004052 | 0.80 | ESR1 (0.65) | PTPN1SLCO2B1ABCG2ACHEKDM1A | |
| SCHEMBL27161054 | 0.76 | SLCO2B1 (0.69) | PTPN1SLCO2B1KDM1ASYNJ2HPGD | |
| SCHEMBL29369929 | 0.76 | SLCO2B1 (0.69) | PTPN1SLCO2B1KDM1ASYNJ2HPGD | |
| Neophellamuretin SCHEMBL27013455 | 0.74 | ABCG2 (0.66) | PTPN1ABCG2ACHECYP3A4MAPT | |
| Neophellamuretin SCHEMBL30766255 | 0.74 | ABCG2 (0.66) | PTPN1ABCG2ACHECYP3A4MAPT | |
| SCHEMBL1771703 | 0.73 | PTPN1 (0.54) | PTPN1SLCO2B1ACHEKDM1ASYNJ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-11234918-B2 | Methods for botanical and/or algae extraction | BASF CORPORATION (US) | 2022-02-01 | — | — | US | claimed |
| EP-2858641-B1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORP (US) | 2017-09-06 | — | — | EP | claimed |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2015-05-21 | — | — | US | claimed |
| EP-2858641-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF Corporation (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013184884-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORPORATION (US) | 2013-12-12 | — | — | WO | claimed |
| JP-3005423-A | — | — | None | — | — | JP | disclosed |
| CN-118620789-B | Lactococcus lactis and application thereof in ganoderma lucidum spore fermentation | 四川大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-118620789-A | Lactococcus lactis and application thereof in ganoderma lucidum spore fermentation | 四川大学 | 2024-09-10 | — | — | CN | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | disclosed |
| US-11234918-B2 | Methods for botanical and/or algae extraction | BASF CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-10981084-B2 | Use of coconut water as extraction solvent | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2021-04-20 | — | — | US | disclosed |
| EP-2003968-A2 | COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PRODUCTS, SO INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF | Leschot Sanhueza, Andres Antonio (CL) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | NAPPA ALVARO O | 2007-10-04 | — | — | US | disclosed |
| WO-2007110801-A2 | COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PORDUCTS, INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF | LESCHOT SANHUEZA ANDRES ANTONI (CL) | 2007-10-04 | — | — | WO | disclosed |
| US-6329189-B1 | FOR CATALYZING REACTION BETWEEN AN EPOXY RING OF AN EPOXYSUCCINIC ACID AND PHENOLIC HYDROXYL GROUP OF FLAVONOID, OR A FLAVONOID ANALOGOUS COMPOUND TO FORM TARTARIC ACID ETHER WHICH IS USED IN FOOD AND DRUG INDUSTRY | KIKKOMAN CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-0742012-A2 | Pharmaceutical composition containing substance inhibiting HSP47 production | Kureha Chemical Industry Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| JP-H035423-A | LIPID PEROXIDE PRODUCTION-INHIBITING AGENT CONTAINING FLAVONOID | ICHIMARU PHARCOS CO LTD | 1991-01-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | ALG1, ALG8, CUTA | PTPN1 4794/4885SLCO2B1 4826/4885SLC28A3 4631/4885 |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | C5, PNN, NQO1 | PTPN1 4141/4885SLCO2B1 4682/4885SLC28A3 4597/4885 |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | ALG1, ALG8, CUTA | PTPN1 4794/4885SLCO2B1 4826/4885SLC28A3 4631/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | PTPN1 1318/4885SLCO2B1 976/4885SLC28A3 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.